New drug combo shows promise for tough lung cancer
NCT ID NCT05001971
First seen Jan 16, 2026 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tested a combination of two drugs, anlotinib and penpulimab, in 65 people with small cell lung cancer whose disease had worsened after first-line platinum chemotherapy. The goal was to see if the combination could shrink tumors or slow cancer growth. Participants received the drugs as a second-line treatment, and researchers measured response rates, survival, and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nong Yang
Changsha, Hunan, 410000, China
Conditions
Explore the condition pages connected to this study.